Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 1;82(1):57-65.
doi: 10.1001/jamapsychiatry.2024.3062.

Deconstructing Cognitive Impairment in Psychosis With a Machine Learning Approach

Affiliations

Deconstructing Cognitive Impairment in Psychosis With a Machine Learning Approach

Robert A McCutcheon et al. JAMA Psychiatry. .

Abstract

Importance: Cognitive functioning is associated with various factors, such as age, sex, education, and childhood adversity, and is impaired in people with psychosis. In addition to specific effects of the disorder, cognitive impairments may reflect a greater exposure to general risk factors for poor cognition.

Objective: To determine the extent that impairments in cognition in psychosis reflect risk factor exposures.

Design, setting, and participants: This cross-sectional study examined the relationship between exposures and cognitive function using data from the Bipolar-Schizophrenia Network on Intermediate Phenotypes studies 1 and 2 across 6 sites. Participants included healthy controls; patients with schizophrenia, schizoaffective disorder, or bipolar I disorder with psychosis; and relatives of patients. Predictive modeling was performed using extreme gradient boosting regression to train a composite cognitive score prediction model with nested cross-validation. Shapley additive explanations values were used to examine the relationship between exposures and cognitive function.

Exposure: Exposures were chosen based on associations with cognition previously identified: age, sex, race and ethnicity, childhood adversity, education, parental education, parental socioeconomic status, parental age at birth, substance use, antipsychotic dose, and diagnosis.

Main outcomes and measures: Cognition was assessed using the Brief Assessment of Cognition in Schizophrenia.

Results: A total of 3370 participants were included: 840 healthy controls, 709 patients with schizophrenia, 541 with schizoaffective disorder, 457 with bipolar I disorder with psychosis, and 823 relatives of patients. The mean (SD) age was 37.9 (13.3) years; 1887 were female (56%) and 1483 male (44%). The model predicted cognitive scores with high accuracy: out-of-sample Pearson correlation between predicted and observed cognitive composite score was r = 0.72 (SD = 0.03). Individuals with schizophrenia (z = -1.4), schizoaffective disorder (z = -1.2), and bipolar I disorder with psychosis (z = -0.5) all had significantly worse cognitive composite scores than controls. Factors other than diagnosis and medication accounted for much of this impairment (schizophrenia z = -0.73, schizoaffective disorder z = -0.64, bipolar I disorder with psychosis z = -0.13). Diagnosis accounted for a lesser proportion of this deficit (schizophrenia z = -0.29, schizoaffective disorder z = -0.15, bipolar I disorder with psychosis z = -0.13), and antipsychotic use accounted for a similar deficit across diagnostic groups (schizophrenia z = -0.37, schizoaffective disorder z = -0.33, bipolar I disorder with psychosis z = -0.26).

Conclusions and relevance: This study found that transdiagnostic factors accounted for a meaningful share of the variance in cognitive functioning in psychosis. A significant proportion of the cognitive impairment in psychosis may reflect factors relevant to cognitive functioning in the general population. When considering interventions, a diagnosis-agnostic, symptom-targeted approach may therefore be appropriate.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr McCutcheon has received speaker/consultancy fees from Boehringer Ingelheim, Janssen, Karuna, Lundbeck, Otsuka, and Viatris and codirects a company that designs digital resources to support treatment of mental ill health. Dr Keefe reported advisory board fees from Boehringer Ingelheim, Merck, Karuna, Pangea, and Sirtsei; nonfinancial support for travel to conferences from Boehringer Ingelheim; consulting fees from WCG, Gedeon Richter, Recognify, Vandria, and Kynexis outside the submitted work and having had a patent for VRFCAT with royalties paid from WCG and a patent for BACS with royalties paid from WCG. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Association of Predictor Variables and Within-Diagnosis Cognitive Performance
The width of the bars represents the relative contribution of the variable to the total Shapley additive explanation (SHAP) value within the diagnostic group (the education bar includes word reading score). For example, the relatively wide bar representing education indicates that education makes a major contribution to the prediction for cognitive performance within a diagnosis. Variables that are relatively constant within a group (eg, diagnosis) will contribute minimally here, although they may contribute markedly to between-group predictions. The chart represents the contribution of each variable to model predictions; ie, it does not imply that these variables explain 100% of variance in cognitive scores. A, The model included all predictor variables. B, The model did not include participant substance use, education level, or word reading score.
Figure 2.
Figure 2.. Association of Predictor Variables and Cognitive Impairment
For each diagnostic group, the bar represents the extent in terms of z score to which that variable contributes to cognitive impairment relative to the control cohort. Bars to the right of 0 indicate that in this cohort the variable has a net protective effect. A, The model included all predictor variables. B, The model did not include participant substance use, education level, or word reading score.
Figure 3.
Figure 3.. Association Between Antipsychotic Exposure and Prediction of Cognitive Performance
Shapley additive explanation (SHAP) values associated with medication exposure from models fit to a subsample of individuals with schizophrenia or schizoaffective disorder. Increasing antipsychotic dose is associated with an increasingly negative influence on prediction of cognitive performance.

References

    1. McCutcheon RA, Keefe RSE, McGuire PK. Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment. Mol Psychiatry. 2023;28(5):1902-1918. doi: 10.1038/s41380-023-01949-9 - DOI - PMC - PubMed
    1. Keefe RSE, Harvey PD. Cognitive impairment in schizophrenia. Handb Exp Pharmacol. 2012;(213):11-37. doi: 10.1007/978-3-642-25758-2_2 - DOI - PubMed
    1. Li W, Zhou FC, Zhang L, et al. Comparison of cognitive dysfunction between schizophrenia and bipolar disorder patients: a meta-analysis of comparative studies. J Affect Disord. 2020;274(March):652-661. doi: 10.1016/j.jad.2020.04.051 - DOI - PubMed
    1. Catalan A, Radua J, McCutcheon R, et al. Examining the variability of neurocognitive functioning in individuals at clinical high risk for psychosis: a meta-analysis. Transl Psychiatry. 2022;12(1):198. doi: 10.1038/s41398-022-01961-7 - DOI - PMC - PubMed
    1. Catalan A, McCutcheon RA, Aymerich C, et al. The magnitude and variability of neurocognitive performance in first-episode psychosis: a systematic review and meta-analysis of longitudinal studies. Transl Psychiatry. 2024;14(1):15. doi: 10.1038/s41398-023-02718-6 - DOI - PMC - PubMed